PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Diffuse Large B-Cell Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
Detailed description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).
Primary outcome measures
- The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma [Time frame: Baseline and 2 weeks after treatment]
- Standardized uptake value (SUV) [Time frame: Baseline and 2 weeks after treatment]
Secondary outcome measures (2)
- Progress free suivival [Time frame: 3 years]
- Overall survival [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Pathologic diagnosis of DLBCL
- Patient's general condition is good and survival is expected to be greater than six months
- Signed and dated informed consent form
Exclusion criteria
- Combined with other malignant tumors
- Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
- Pregnant women and women at risk of pregnancy, breastfeeding women
- poor compliant
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
China · 1 center
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School — Shanghai
Identifiers
NCT: NCT06755775 · RuijinH 2024-254